

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person* Geist William			2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ PRESIDENT, PROTEIN SCIENCES		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 08/15/2022			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
614 MCKINLEY PL N E			4. If Amendment, Date Original Filed (Month/Day/Year)					
(Street) MINNEAPOLIS, MN 55413								
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned					

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								2,490 (1)	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Restricted Stock Units	(2)	08/15/2022		A		1,785		(3)	(3)	Common Stock	1,785	\$ 0	1,785	D	
Stock Options (Right to Buy)	\$ 378.08	08/15/2022		A		5,550		(3)	08/15/2029	Common Stock	5,550	\$ 0	5,550	D	
Stock Options (Right to Buy)	\$ 378.08	08/15/2022		A		7,400		(4)	08/15/2029	Common Stock	7,400	\$ 0	7,400	D	
Restricted Stock Units	(2)							(3)	(3)	Common Stock	840		840	D	
Stock Options (Right to Buy)	\$ 401.57							(3)	02/01/2029	Common Stock	2,984		2,984	D	
Stock Options (Right to Buy)	\$ 401.57							(5)	02/01/2029	Common Stock	3,978		3,978	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Geist William 614 MCKINLEY PL N E MINNEAPOLIS, MN 55413			PRESIDENT, PROTEIN SCIENCES	

Signatures

/s/ Brenda S. Furlow as Attorney-in-Fact for William Geist pursuant to Power of Attorney previously filed		08/17/2022
<small>**Signature of Reporting Person</small>		<small>Date</small>

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents 2,490 shares of restricted stock for which the risk of forfeiture will lapse as to 830 shares on each of February 1, 2023, February 1, 2024 and February 1, 2025.
- (2) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (3) Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (4) Options to purchase 1,850 shares vest on each of 8/15/2023, 8/15/2024, 8/51/2025 and 8/15/2026.
- (5) Options to purchase 995 shares vest on each of 2/1/2023 and 2/1/2024 and options to purchase 994 shares vest on each of 2/1/2025 and 2/1/2026.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.